SRZNW (SRZNW) Stock Price & Analysis
SRZNW (SRZNW) rose 153.33% to USD 0 as of September 9, 2026 at 13:29 UTC, according to Nexqual real-time market data.
SRZNW last closed at USD 0; the session ranged USD 0–0 on volume of 26,468 shares. Market capitalization is —, with a 52-week range of USD 0–0 (NCM). Source: Nexqual, September 9, 2026 at 13:29 UTC.
Key Statistics (as of September 9, 2026 at 13:29 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 153.33% (up) |
| Previous Close | USD 0 |
| Open | USD 0.01 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 26,468 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (SRZNW)
Wall Street analysts rate SRZNW "None", per Nexqual as of September 9, 2026 at 13:29 UTC.
| Consensus Rating | None |
|---|
Earnings (SRZNW)
| Revenue Estimate | $373,800 |
|---|
Source: Nexqual, September 9, 2026 at 13:29 UTC.
Financials & Fundamentals (SRZNW)
| Total Revenue | $11.51M |
|---|---|
| Revenue Growth (YoY) | +408.60% |
| Gross Margin | -200.38% |
| Operating Margin | -207.40% |
| Profit Margin | +0.00% |
| Current Ratio | 12.14 |
| Total Cash | $102.04M |
| Total Debt | $6.32M |
| Free Cash Flow | $-21.75M |
Source: Nexqual, September 9, 2026 at 13:29 UTC.
Financial Health Score (SRZNW)
Nexqual rates SRZNW's overall financial health "Weak" across five dimensions, as of September 9, 2026 at 13:29 UTC.
| Growth | Critical — Revenue -67% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $102M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$22M, burning cash |
| Efficiency | Mixed — No data |
Ownership (SRZNW)
| Float | 4.62M |
|---|
Source: Nexqual, September 9, 2026 at 13:29 UTC.
Leadership (SRZNW)
SRZNW is led by Craig C. Parker (age 63), CEO, President & Director, per Nexqual as of September 9, 2026 at 13:29 UTC.
| CEO, President & Director | Craig C. Parker (age 63) |
|---|---|
| COO & Corporate Secretary | Charles Williams (age 45) |
| Executive Vice President of Research | Yang Li (age 56) |
| Chief Financial Officer | Andrew Maleki (age 35) |
| Senior Vice President of Development Operations | Michael Lauw M.S.W. |
Major Backers & Investors (SRZNW)
Notable institutional backers of SRZNW include Baker Bros. Advisors, LP, LMR Partners LLP, Bridger Management LLC, according to Nexqual as of September 9, 2026 at 13:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 14.11% |
| LMR Partners LLP | 10.97% |
| Bridger Management LLC | 7.48% |
| Euclidean Capital Llc | 2.89% |
| Deerfield Management Company, L.P | 2.82% |
| Perceptive Advisors Llc | 2.82% |
| SymBiosis Capital Partners, LLC | 2.54% |
| ArrowMark Colorado Holdings LLC | 1.83% |
Source: Nexqual, September 9, 2026 at 13:29 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRZN | Surrozen, Inc. | USD 20.68 | ▼ 8.25% |
| JSPRW | Jasper Therapeutics, Inc. | USD 0.01 | ▼ 19.57% |
| HUMAW | Humacyte, Inc. | USD 0 | ▼ 78.05% |
| SABSW | SAB Biotherapeutics, Inc. | USD 0.02 | ▼ 22.88% |
| REVBW | Revelation Biosciences, Inc. | USD 0.01 | ▲ 44.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 13:29 UTC. This page is informational and not investment advice.